Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management

Oncotarget. 2018 Nov 30;9(94):36652-36653. doi: 10.18632/oncotarget.26413.

Authors

Salvatore Lopez¹, Burak Zeybek¹, Alessandro D Santin¹

Affiliation

¹ Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.

No abstract available

Keywords: HER2/neu; USC; endometrial cancer; trastuzumab; uterine serous carcinoma.

Publication types

Editorial